Skip to main content
Clinical Trials/NCT03761680
NCT03761680CompletedNot Applicable

MEDPass Trial: MEDPass Versus Conventional Administration of Oral Nutritional Supplements: A RCT Comparing Energy and Protein Intake

Insel Gruppe AG, University Hospital Bern2 sites in 1 country204 target enrollmentStarted: November 22, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
204
Locations
2
Primary Endpoint
Average intake of energy / day (kcal, % of calculated daily requirement)

Study Overview

Brief Summary

The aim of the randomized-controlled, single-center MEDPass trial is to assess the effects of MEDPass versus conventional administration of oral nutritional supplements (ONS) on energy and protein intake in medical and geriatric inpatients.

Detailed Description

Disease related malnutrition (DRM) in hospitalized patients is a common problem.The oral nutritional support with ONS is one of the first and most common treatment approach in the patients at nutritional risk. Treatment with ONS may reduce mortality and complications in hospitalized patients.

There are no standards on the type of administration of ONS in terms of timing throughout the day leading to individual approaches. ONS are conventionally served as snacks by nurses, nursing aids or gastronomy personnel between the main meals. The MEDPass-mode offers a different approach by serving ONS together with the medication, three or four times per day, in unusually small portions. Preliminary trials suggest that compliance and cost effectiveness may be improved with the MEDPass-mode.

Enhancing compliance to ONS may not consequently lead to improved total energy and protein intake throughout the day. There has never been a large trial in which total energy- and protein intake of the subjects was studied consequently and systematically throughout the hospitalization. Therefore, this trial will bridge this gap by studying total energy- and protein intake as primary outcomes.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
19 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Nutritional risk screening (NRS-2002) total score ≥3 points according to routine screening at admission within 72 hours
  • Expected hospital LOS ≥3 days after screening (as estimated by the treating physician)
  • Patient qualifies for ONS and approves prescription
  • Age >18 years
  • Willingness and ability to provide informed consent

Exclusion Criteria

  • Initially admitted to critical care unit
  • Immediate post-operative phase (<7 days post-surgery)
  • Dysphagia with the inability to swallow liquids
  • Supplemental enteral and/or parenteral nutrition
  • Admitted with, or scheduled for, total parenteral nutrition or tube feeding
  • Mini Mental State examination < 16 points
  • hospitalized due to anorexia nervosa
  • hospitalized due to acute pancreatitis
  • hospitalized due to acute liver failure
  • cystic fibrosis
  • patients after gastric bypass surgery
  • patients with short bowel syndrome
  • terminal condition (end of life situation)
  • poor skills in German language (study language)

Outcomes

Primary Outcomes

Average intake of energy / day (kcal, % of calculated daily requirement)

Time Frame: throughout the hospitalization: min. 3 to max. 30 days

Secondary Outcomes

  • Average intake of protein /day (g, % of calculated daily requirement)(throughout the hospitalization: min. 3 to max. 30 days)
  • Average intake of ONS / day (ml)(throughout the hospitalisation: min. 3 to max. 30 days)
  • Development of hand grip strength (kg)(throughout the hospitalisation: min. 3 to max. 30 days)
  • Changes in body weight (kg)(throughout the hospitalisation: min. 3 to max. 30 days)
  • Development of appetite visual analogue scale (VAS)-score (cm)(throughout the hospitalisation: min. 3 to max. 30 days)
  • Development of nausea visual analogue scale (VAS)-score (cm)(throughout the hospitalisation: min. 3 to max. 30 days)
  • Hospital length of stay (LOS)(hospitalization, max. 30 days)
  • Mortality(30 days)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials